Affiliations: [a] State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China | [b] Department of Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Correspondence:
[*]
Corresponding authors: Yao Li, State Key Laboratory of Genetic Engineering,
Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Tel.: +86 21 65642047; Fax: +86 21 65642502;
E-mail:yaoli@fudan.edu.cn; Xuechao Wan,
Tel.:+86 2151630560; E-mail:14110700025@fudan.edu.cn
Note: [1] Both authors contributed equally to this work.
Abstract: Prostate cancer (PCa) was one of the most common cancers in males in China.
Long non-coding RNAs (lncRNA), a class of non-coding RNAs with more than 200
nucleotides, played key roles in the progression of prostate cancer. GLIDR,
a novel long intergenic ncRNA, was found to be upregulated in tumors
compared to normal tissues by using publically databases. In the clinical
validation cohort, our results showed GLIDR was significantly up-regulated
in prostate cancer samples and cell lines. To explore the potential
functions of the GLIDR, we constructed gene co-expression networks and
applied GO analysis. Our analysis revealed that GLIDR was involved in the
regulation of translational elongation, transcription, rRNA processing, RNA
splicing, signal transduction, and cell adhesion. Furthermore, a
GLIDR-mediated ceRNA network in prostate cancer was also identified. We
believed that this study still provided some clues in exploring new
therapeutic and prognostic targets for prostate cancer.
